MLAB trades 14.2% above Wall Street's consensus target of $110.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes MLAB achieves its forward estimates and maintains a stable P/E multiple of 14.1x. This scenario reflects the blended consensus of 8 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 8, 2026, Mesa Laboratories, Inc. (MLAB) has a Wall Street consensus price target of $110.00, based on estimates from 8 covering analysts. With the stock currently trading at $128.25, this represents a potential downside of -14.2%. The company has a market capitalization of $718M.
Analyst price targets range from a low of $110.00 to a high of $110.00, representing a 0% spread in expectations. The median target of $110.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Hold, with 3 analysts rating the stock as a Buy or Strong Buy,5 rating it Hold, and 0 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, MLAB trades at a trailing P/E of 153.8x and forward P/E of 14.1x. The forward PEG ratio of 1.04 indicates reasonable valuation for growth. Analysts expect EPS to grow +987.2% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $67.85, with bear and bull scenarios of $42.74 and $89.39 respectively. Model confidence stands at 44/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 NEOGNeogen Corporation | $2.6B | $11.76 | $13.50 | +14.8% | Buy | 35.3x | 11 |
 LFUSLittelfuse, Inc. | $9.0B | $355.72 | $518.33 | +45.7% | Buy | 19.3x | 12 |
 NOVTNovanta Inc. | $4.8B | $135.15 | $194.00 | +43.5% | Buy | 36.6x | 3 |
 RGENRepligen Corporation | $9.8B | $173.49 | $198.00 | +14.1% | Buy | 83.7x | 24 |
 TRMBTrimble Inc. | $12.6B | $54.11 | $72.60 | +34.2% | Buy | 17.5x | 28 |
 BIOBio-Rad Laboratories, Inc. | $10.3B | $381.57 | $350.00 | -8.3% | Buy | 38.2x | 14 |
 IDXXIDEXX Laboratories, Inc. | $53.3B | $676.04 | $716.67 | +6.0% | Buy | 45.5x | 23 |
 BRKRBruker Corporation | $9.3B | $61.31 | $67.00 | +9.3% | Buy | 28.9x | 33 |
 FELEFranklin Electric Co., Inc. | $4.2B | $94.17 | $132.50 | +40.7% | Hold | 20.3x | 11 |
 OSISOSI Systems, Inc. | $3.2B | $196.36 | $269.50 | +37.2% | Buy | 18.8x | 18 |
Quick answers to the most common questions about buying MLAB stock.
MLAB's consensus price target is $110, -14.2% below the current price of $128.25. The 8 analysts tracking MLAB see downside risk at present valuations.
MLAB has a consensus rating of "Hold" based on 8 Wall Street analysts. The rating breakdown is mixed, with 5 Hold ratings making up the largest segment. The consensus 12-month price target of $110 implies -14.2% downside from current levels.
With a forward P/E of 14.1478x, MLAB trades at a relatively low valuation. The consensus target of $110 implies -14.2% move, suggesting the market may be pricing in risks.
The most bullish Wall Street analyst has a price target of $110 for MLAB, while the most conservative target is $110. The consensus of $110 represents the median expectation. Our quantitative valuation model projects a bull case target of $89 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
MLAB is moderately covered, with 8 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 3 have Buy ratings, 5 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month MLAB stock forecast based on 8 Wall Street analysts shows a consensus price target of $110, with estimates ranging from $110 (bear case) to $110 (bull case). The median consensus rating is "Hold". Our proprietary valuation model produces a base case fair value of $68, with bear/bull scenarios of $43/$89.
Our quantitative valuation model calculates MLAB's fair value at $68 (base case), with a bear case of $43 and bull case of $89. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 44/100.
MLAB trades at a forward P/E ratio of 14.1x based on next-twelve-months earnings estimates compared to a trailing P/E of 153.8x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Analysts are cautious on MLAB, with 0 Sell ratings and a price target of $110 (-14.2% from current price). The "Hold" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
MLAB analyst price targets range from $110 to $110, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $110 consensus represents the middle ground. Our model's $43-$89 range provides an independent fundamental perspective.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.